
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year's report. The AMR Benchmark evaluates ph.


















